Top

Published in:

01-11-2015 | Maternal-Fetal Medicine

Maternal serum copeptin, MR-proANP and procalcitonin levels at 11–13 weeks gestation in the prediction of preeclampsia

Authors: Cahit Birdir, Katharina Janssen, Anca Daniela Stanescu, Antje Enekwe, Sabine Kasimir-Bauer, Alexandra Gellhaus, Rainer Kimmig, Angela Köninger

Published in: Archives of Gynecology and Obstetrics | Issue 5/2015

Abstract

Purpose

We investigated the potential value of maternal serum copeptin, midregional proatrial natriuretic peptide (MR-proANP) and Procalcitonin (PCT) levels at 11–13 weeks’ gestation in the prediction of preeclampsia (PE) in a case–control study.

Materials and methods

Maternal serum concentration of copeptin, MR-proANP and PCT were measured at 11–13 weeks’ gestation in cases of PE (n = 35) and controls (n = 100). The PE group was divided into early-onset PE (EO-PE) and late-onset PE (LO-PE). From the regression model, the value in each case and control was expressed as a multiple of the expected median (MoM). The Mann–Whitney test was used to determine the significance of differences in the median MoM in each outcome group from that in the controls.

Results

In the PE group, compared to controls, maternal serum concentrations of copeptin, MR-proANP and PCT were not significantly different.

Conclusion

The maternal serum copeptin, MR-proANP and PCT levels are higher in EO-PE and LO-PE patients, but the difference is not significant. Thus, their levels in first trimester are not proven to be effective markers to screen for PE.

Morgenthaler NG, Struck J, Jochberger S, Dünser MW (2008) Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab 19:43–49CrossRefPubMed

Zulfikaroglu E, Islimye M, Tonguc EA, Payasli A, Isman F et al (2011) Circulating levels of copeptin, a novel biomarker in pre-eclampsia. J Obstet Gynaecol Res 37(9):1198–1202. doi:10.1111/j.1447-0756.2010.01498.x Epub 2011 Apr 19 CrossRefPubMed

Bernasconi M, Tamm M, Bingisser R, Miedinger D, Leuppi J et al (2011) Midregional proatrial natriuretic peptide predicts survival in exacerbations of COPD. Chest 140:91–99CrossRefPubMed

Adnot S, Andrivet P, Chabrier PE, Piquet J, Plas P et al (1989) Atrial natriuretic factor in chronic obstructive lung disease with pulmonary hypertension. Physiological correlates and response to peptide infusion. J Clin Invest 833:986–993CrossRef

de Zeeuw D, Janssen WM, de Jong PE (1992) Atrial natriuretic factor: its (patho)physiological significance in humans. Kidney Int 415:1115–1133CrossRef

Edwards BS, Zimmerman RS, Schwab TR, Heublein DM, Burnett JC Jr (1988) Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res 622:191–195CrossRef

Espiner EA, Richards AM, Yandle TG, Nicholls MG (1996) Natriuretic hormones. Endocrinol Metab Clin North Am 243:481–509

Weidmann P, Hasler L, Gnädinger MP, Lange RE, Uehlinger DE et al (1986) Blood levels and renal effects of atrial natriuretic peptide in normal man. J Clin Invest 773:734–742CrossRef

Jin H, Yang RH, Chen YF, Jackson RM, Itoh H et al (1991) Atrial natriuretic peptide in acute hypoxia-induced pulmonary hypertension in rats. J Appl Physiol 713:807–814

10.

Chen YF, Feng JA, Li P, Xing D, Ambalavanan N et al (2006) Atrial natriuretic peptide-dependent modulation of hypoxia-induced pulmonary vascular remodeling. Life Sci 7914:1357–1365CrossRef

11.

Lordick F, Hauck RW, Senekowitsch R, Emslander HP (1995) Atrial natriuretic peptide in acute hypoxia-exposed healthy subjects and in hypoxaemic patients. Eur Respir J 82:216–221CrossRef

12.

Easterling TR, Benedetti TJ, Schmucker BC, Millard SP (1990) Maternal hemodynamics in normal and preeclamptic pregnancies: a longitudinal study. Obstet Gynecol 76:1061–1069PubMed

13.

Bosio PM, McKenna PJ, Conroy R, O’Herlihy C (1999) Maternal central hemodynamics in hypertensive disorders of pregnancy. Obstet Gynecol 94:978–984CrossRefPubMed

14.

National Institute for Health and Clinical Excellence (2004) Hypertension: management of adults in primary care: pharmacological update. Clinical Guideline 18. NICE, London

15.

De Paco C, Kametas N, Rencoret G, Strobl I, Nicolaides KH (2008) Maternal cardiac output between 11 and 13 weeks of gestation in the prediction of preeclampsia and small for gestational age. Obstet Gynecol 111:292–300CrossRefPubMed

16.

Schneider HG, Lam QT (2007) Procalcitonin for the clinical laboratory: a review. Pathology 39:383–390CrossRefPubMed

17.

Herzum I, Renz H (2008) Inflammatory markers in SIRS, sepsis and septic shock. Curr Med Chem 15:581–587CrossRefPubMed

18.

Torbe A (2007) Maternal plasma procalcitonin concentrations in pregnancy complicated by preterm premature rupture of membranes. Mediators Inflamm 2007:35782PubMedPubMedCentral

19.

Montagnana M, Lippi G, Albiero A, Scevarolli S, Salvagno GL et al (2008) Procalcitonin values in preeclamptic women are related to severity of disease. Clin Chem Lab Med 46:1050–1051PubMed

20.

Can M, Sancar E, Harma M, Guven B, Mungan G et al (2011) Inflammatory markers in preeclamptic patients. Clin Chem Lab Med 49:1469–1472CrossRefPubMed

21.

Gulec UK, Ozgunen FT, Guzel AB, Buyukkurt S, Seydaoglu G et al (2012) An analysis of C-reactive protein, procalcitonin, and D-Dimer in pre-eclamptic patients. Am J Reprod Immunol 68:331–337CrossRef

22.

Borzychowski AM, Sargent IL, Redman CW (2006) Inflammation and pre-eclampsia. Semin Fetal Neonatal Med 11:309–316CrossRefPubMed

23.

Dandona P, Nix D, Wilson MF, Aljada A, Love J et al (1994) Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 79:1605–1608PubMed

24.

ACOG Committee on Practice Bulletins-Obstetrics (2002) ACOG practice bulletin: diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol 99:159–167CrossRef

25.

Brosens I, Robertson WB, Dixon HG (1967) The physiological response of the vessels of the placental bed to normal pregnancy. J Pathol Bacteriol 93:569–579CrossRefPubMed

26.

Khong TY, De Wolf F, Robertson WB, Brosens I (1986) Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 93:1049–1059CrossRefPubMed

27.

Pijnenborg R, Anthony J, Davey DA et al (1991) Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol 98:648–655CrossRefPubMed

28.

Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH (2009) First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 53:812–818CrossRefPubMed

29.

Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH (2011) Prediction of early, intermediate and late preeclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks. Prenat Diagn 31:66–74CrossRefPubMed

30.

Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH (2013) Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther 33(1):8–15. doi:10.1159/000341264 Epub 2012 Aug 16 CrossRefPubMed

31.

Koopmans CM, Bijlenga D, Groen H, Vijgen SM, Aarnoudse JG et al (2009) Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks’ gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet 374(9694):979–988. doi:10.1016/S0140-6736(09)60736-4 Epub 2009 Aug 3 CrossRefPubMed

32.

Robinson HP, Fleming JE (1975) A critical evaluation of sonar crown rump length measurements. Br J Obstet Gynaecol 182:702–710CrossRef

33.

Nicolaides KH (2011) Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn 31:7–15CrossRefPubMed

34.

Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM (2001) The classification and diagnosis of the hypertensive disor- ders of pregnancy: statement from the inter- national society for the study of hypertension in pregnancy (ISSHP). Hypertens Pregnancy 20:IX–XIV

35.

Foda AA, Abdel Aal IA (2012) Maternal and neonatal copeptin levels at cesarean section and vaginal delivery. Eur J Obstet Gynecol Reprod Biol 165(2):215–218. doi:10.1016/j.ejogrb.2012.08.012 Epub 2012 Aug 22 CrossRefPubMed

36.

Katan M, MülerB CrainMC (2008) Copeptin a new and promising diagnostic and prognostic marker. Critical Care 12:117–118CrossRefPubMedPubMedCentral

37.

Easterling TR, Benedetti TJ (1989) Preeclampsia: a hyperdynamic disease model. Am J Obstet Gynecol 160:1447–1453CrossRefPubMed

38.

Savvidou MD, Kametas NA, Donald AE, Nicolaides KH (2000) Non-invasive assessment of endothelial function in normal pregnancy. Ultrasound Obstet Gynecol 15:502–507CrossRefPubMed

39.

Borzychowski AM, Sargent IL, Redman CW (2006) Inflammation and pre-eclampsia. Semin Fetal Neonatal Med 11:309–316CrossRefPubMed

40.

Roberts JM, Hubel CA (2004) Oxidative stress in preeclampsia. Am J Obstet Gynecol 190:1177–1178CrossRefPubMed

41.

Benedetto C, Marozio L, Tavella AM, Salton L, Grivon S et al (2010) Coagulation disorders in pregnancy: acquired and inherited thrombophilias. Ann N Y Acad Sci 1205:106–117CrossRefPubMed

42.

Kharb S, Gulati N, Singh V, Singh GP (1998) Lipid peroxidation and vitamin E levels in preeclampsia. Gynecol Obstet Invest 46:238–240CrossRefPubMed

43.

Wright D, Akolekar R, Syngelaki A, Poon LCY, Nicolaides KH (2012) A competing risks model in early screening for preeclampsia. Fetal Diagn Ther. doi:10.1159/000338470

44.

Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F et al (2010) Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 116:402–414CrossRefPubMed

45.

Roberge S, Villa P, Nicolaides KH, Giguère Y, Vainio M et al (2012) Early administration of low dose aspirin for the prevention of preterm and term pre-eclampsia: a systematic review and meta- analysis. Fetal Diagn Ther 31:141–146CrossRefPubMed

Title: Maternal serum copeptin, MR-proANP and procalcitonin levels at 11–13 weeks gestation in the prediction of preeclampsia
Authors: Cahit Birdir
Katharina Janssen
Anca Daniela Stanescu
Antje Enekwe
Sabine Kasimir-Bauer
Alexandra Gellhaus
Rainer Kimmig
Angela Köninger
Publication date: 01-11-2015
Publisher: Springer Berlin Heidelberg
Published in: Archives of Gynecology and Obstetrics / Issue 5/2015
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-015-3745-7

2024 ASCO Annual Meeting

Springer Medicine

Maternal serum copeptin, MR-proANP and procalcitonin levels at 11–13 weeks gestation in the prediction of preeclampsia

Abstract

Purpose

Materials and methods

Results

Conclusion

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2015

Myo-inositol is a promising treatment for the prevention of ovarian hyperstimulation syndrome (OHSS): an animal study

The effects of progesterone in women undergoing preterm labor

Is pain better tolerated with mini-hysteroscopy than with conventional device? A systematic review and meta-analysis

AK000953 silencing can enhance the killing effect of danazol on uterine fibroids

Uterine compression sutures theory

Placental growth factor concentration in maternal circulation decreases after fetal death: lessons from a case series study